{
    "clinical_study": {
        "@rank": "14857", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: RO5503781", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 2: RO5503781 + Cytarabine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 3: RO5503781 + Cytarabine + Anthracycline", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This phase I/IB, open-label study will evaluate the safety and pharmacokinetics of\n      escalating doses of RO5503781 as single agent or in combination with cytarabine in patients\n      with acute myelogenous leukemia. An optional Part 3 in which RO5503781 is administered with\n      cytarabine and anthracycline may be considered."
        }, 
        "brief_title": "A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelogenous Leukemia, Acute", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Documented/confirmed acute myelogenous leukemia (AML), except for acute promyelocytic\n             leukemia\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 in Part 1 and\n             Part 2, patients enrolled in the extension/tail portion must have an ECOG performance\n             status of 0 or 1\n\n          -  All non-hematological adverse events of any prior chemotherapy, surgery or\n             radiotherapy must have resolved to NCI-CTCAE Grade </=2 prior to starting therapy\n\n          -  Adequate hepatic and renal function\n\n          -  Willing to submit the blood sampling and bone marrow sampling required by protocol\n             Additional inclusion criteria for Parts 1-3 may apply.\n\n        Exclusion Criteria:\n\n          -  Patients receiving any other investigational or commercial agents or therapies\n             administered with the intention to treat their malignancy within 14 days of first\n             receipt of study drug, with the exception of hydroxyurea as defined in protocol\n\n          -  History of allergic or toxic reactions attributed to cytarabine (Part 2) or history\n             of allergic reactions to components of the formulated product\n\n          -  Current evidence of central nervous system (CNS) leukemia\n\n          -  Patients with severe and/or uncontrolled medical conditions or other conditions that\n             could affect their participation in the study\n\n          -  Patients with evidence of electrolyte imbalance of Grade >/= 2 which cannot be\n             corrected prior to study initiation\n\n          -  Pregnant or breastfeeding women\n\n          -  HIV-positive patients receiving anti-retroviral therapy\n\n          -  Patients who refuse to potentially receive blood products and/or have a\n             hypersensitivity to blood products Additional exclusion criteria for Parts 1-3 may\n             apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773408", 
            "org_study_id": "NP28679", 
            "secondary_id": "2012-004882-41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part 1: RO5503781", 
                    "Part 2: RO5503781 + Cytarabine"
                ], 
                "description": "multiple escalating doses", 
                "intervention_name": "RO5503781", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2: RO5503781 + Cytarabine", 
                "description": "1000 mg/m2 iv daily for 6 days each cycle", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: RO5503781", 
                    "Part 2: RO5503781 + Cytarabine", 
                    "Part 3: RO5503781 + Cytarabine + Anthracycline"
                ], 
                "description": "Antracycline per standard clinical practice", 
                "intervention_name": "Anthracycline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cytarabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valhalla", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10595"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3002"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3T 1E2"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "Emilia-Romagna", 
                        "zip": "40138"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "zip": "G12 0YN"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "France", 
                "Italy", 
                "Korea, Republic of", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: NP28679 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum tolerated dose (MTD)", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Dose-limiting toxicities (DLTs)", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773408"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy: Complete remission", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Efficacy: Partial Response", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Efficacy: Disease progression", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }, 
            {
                "measure": "Pharmacokinetics: Plasma concentrations of RO5503781 alone and in combination with cytarabine", 
                "safety_issue": "No", 
                "time_frame": "first 28-day cycle"
            }, 
            {
                "measure": "Pharmacodynamics: Leukemia-related biomarkers", 
                "safety_issue": "No", 
                "time_frame": "first 28-day cycle"
            }, 
            {
                "measure": "Efficacy: Hematologic malignancy response", 
                "safety_issue": "No", 
                "time_frame": "approximately 1.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}